 Steelcast Ltd posts higher PAT of Rs. 23.21 crores in Q2 FY26
Steelcast Ltd posts higher PAT of Rs. 23.21 crores in Q2 FY26 Schaeffler India Ltd Q3 CY2025 consolidated PAT up at Rs. 289.26 crores
Schaeffler India Ltd Q3 CY2025 consolidated PAT up at Rs. 289.26 crores Tatva Chintan Pharma Chem Ltd consolidated Q2FY26 PAT climbs to Rs. 9.91 crores
Tatva Chintan Pharma Chem Ltd consolidated Q2FY26 PAT climbs to Rs. 9.91 crores GPT Infraprojects Ltd receives contract worth Rs. 37.8 crore
GPT Infraprojects Ltd receives contract worth Rs. 37.8 crore Dr Lal PathLabs Limited recommends 1:1 bonus issue
Dr Lal PathLabs Limited recommends 1:1 bonus issue 
              Svaks Biotech India Pvt Ltd (SBIPL), the Promoter of Lasa Supergenerics Ltd continues to dump its shares through open market selling. The promoter entity sold 1,873 equity shares on Feb 15, 2018 at a price of Rs. 142 which reduced its stake from 106936 equity shares (0.47%)	to 105063 shares (0.46%).
It again sold 6556 equity shares on Feb 16, 2018 at a price of Rs. 135 through open market selling which reduced its stake further from 105063 shares (0.46%) to 98507 shares (0.43%).
Svaks Biotech India Pvt Ltd was holding 3,37,774 equity shares or 1.48% in Lasa as per the shareholding pattern on December 31, 2017.
Shares of Lasa Supergenerics Ltd was last trading in BSE at Rs.122.8 as compared to the previous close of Rs. 129.25. The total number of shares traded during the day was 82077 in over 469 trades.
The stock hit an intraday high of Rs. 128 and intraday low of 122.8. The net turnover during the day was Rs. 10117546.